Emerging drugs for psoriasis

Expert Opinion on Emerging Drugs

Volumn 14, Issue 1, 2009, Pages 145-163

  Naldi, Luigi ^a   Raho, Giovanna ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Biological agents; Immunopathogenesis; Psoriasis; Small molecules; Treatment

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ABATACEPT; ABT 874; AIN 457; AMG 714; ANTIPSORIASIS AGENT; APREMILAST; ART 621; BMS 582949; CC 10004; CERTOLIZUMAB PEGOL; CHAPERONIN; DESORIS; DOXERCALCIFEROL; FLUPHENAZINE DECANOATE; FUMARIC ACID DIMETHYL ESTER; GOLIMUMAB; ILV 094; ISA 247; LESTAURTINIB; LLL 3348; MM 093; MM 0933; MONOCLONAL ANTIBODY; N [4 [2 ETHYL 1 (1H 1,2,4 TRIAZOL 1 YL)BUTYL]PHENYL] 2 BENZOTHIAZOLAMINE; PLACEBO; R 348; RITUXIMAB; SOTRASTAURIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VOCLOSPORIN;

ACNE; ASTHMA; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; KERATINOCYTE; MYELOPROLIFERATIVE DISORDER; PHOTOTHERAPY; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN DISEASE; ANIMAL; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; IMMUNOLOGY; METHODOLOGY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; KERATINOCYTES; PHOTOCHEMOTHERAPY; PSORIASIS;

EID: 65649133544     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210902771334     Document Type: Review

References (109)

1. Schoen MP, Boehnicke WH. Psoriasis. N Engl J Med 2005;352:1899-1912 •• An overview of clinical, pathogenetic and therapeutic aspects of psoriasis with a useful glossary and nice diagrammatic representations of pathogenetic concepts.
2. Iizuka H, Takahashi H, Ishida-Yamamoto A. Psoriatic architecture constructed by epidermal remodeling. J Dermatol Sci 2004;35:93-99 (Pubitemid 38969032)
3. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol 2007;25:510-518 • A review of phenotype characterization of psoriasis. (Pubitemid 350087596)
4. Balasubramaniam P, Berth-Jones J. Erythroderma: 90% skin failure. Hosp Med 2004;65:100-102 (Pubitemid 38943363)
5. Jackson R. The importance of being visually literate: observations on the art and science of making a morphological diagnosis in dermatology. Arch Dermatol 1975;111:632-6 • Pattern recognition as the basis for being a 'visually literate' physician.
6. Jobling R, Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol 2006;126:1438-1440 (Pubitemid 43910355)
7. Coates LC, Helliwell PS. Classification and categorisation of psoriatic arthritis. Clin Rheumatol 2008;27:1211-1216 •• Classification of psoriatic arthritis into five groups has been challenged. This paper makes a case for retaining at least the two subgroups of peripheral and axial disease and possibly, splitting the peripheral disease into oligo- and polyarthritis.
8. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005;129:827-36 • In a cohort of 8072 cases of inflammatory bowel disease, patients had a significantly greater likelihood of having arthritis, asthma, bronchitis, psoriasis, and pericarditis than population controls.
9. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008;20:416-422 •• A review of the scientific literature linking psoriasis to metabolic syndrome and its components, as well as to atherosclerosis and myocardial infarction.
10. Mantovani A. Inflaming metastasis. Nature 2009;457:36-37 •• The link between chronic inflammation and cancer.
11. Kimball AB, Robinson D Jr, Wu Y Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008;217:27-37
12. Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117:1531-1537 (Pubitemid 34032784)
13. Olsen JH, Møller H, Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 1992;27:716-722
14. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-1429 (Pubitemid 37433132)
15. Bell LM, Sedlack R, Beard MC, et al. Incidence of psoriasis in Rochester, Minn 1980-1983. Arch Dermatol 1991;127:1184-1187 • To the best of the authors' knowledge, references 15 and 16 are the only published studies providing data on the incidence of psoriasis.
16. Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007;143:1559-1565 • To the best of the authors' knowledge, references 15 and 16 are the only published studies providing data on the incidence of psoriasis. (Pubitemid 350277774)
17. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:121-128 • A review of epidemiological data on psoriasis. (Pubitemid 38832741)
18. Andressen C, Henseler T. Inheritance of psoriasis. Analysis of 2035 family histories. Hautarzt 1982;33:214-217
19. Duffin KC, Chandran V, Gladman DD, et al. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol 2008;35:1449-1453 •• An updated review from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) genetics committee. (Pubitemid 352000802)
20. Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol 2007;25:563-567 •• A thorough and up-to-date review of available data on linkage analysis studies in psoriasis. (Pubitemid 350087603)
21. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 2007;120:953-959 • This and reference 22 are two papers from a cohort study that confirms the association between BMI, smoking habits, and psoriasis documented in previous case-control studies. (Pubitemid 350011082)
22. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women. Arch Intern Med 2007;167:1670-1675 • This and reference 21 are two papers from a cohort study that confirms the association between BMI, smoking habits, and psoriasis documented in previous case-control studies.
23. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-6 • In spite of methodologic flaws with the use of floating numerator, a widely cited paper first suggesting the existence of a type I and type II psoriasis based on age at onset.
24. EMEA Committee for Proprietary Medical Products. Note for guidance on clinical investigation of medical products indicated for the treatment of psoriasis. CPMP/EWP 2454/02 • A document from the European Medication Agency providing guidelines for conducting clinical trials in psoriasis with registration purposes.
25. Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol 2007;25:547-554 (Pubitemid 350087601)
26. Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004;122:602-607 (Pubitemid 38471324)
27. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210:194-199 (Pubitemid 40529233)
28. Unaeze J, Nijsten T, Murphy A, et al. Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol 2006;126:1480-1489 • A long-term view on quality of life in psoriasis. (Pubitemid 43910363)
29. Farber EM, Nall L. The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148:1-18 •• A seminal paper suggesting prevention of disability in psoriatic patients.
30. Naldi L, Colombo P, Benedetti Placchesi E, et al. Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology 2004;208:38-42 • A population survey of skin disease in Italy. (Pubitemid 38142332)
31. Menter A, Griffiths CEM. Current and future management of psoriasis. Lancet 2007;370:272-284 •• An authoritative review of pharmacological management strategies. (Pubitemid 47071926)
32. Naldi L, Minelli C. Dermatology. In: Machin D, Day S, Green S, editors, Textbook of clinical trials. John Wiley and sons, Ltd, Chichester, England 2006. p 263-285
33. Lambert MF, Wood J. Incorporating patient preferences into randomized trials. J Clin Epidemiol 2000;53:163-166 • When designing trials, an important ethical and practical concern is ensuring that proper consideration is given to patient preferences. (Pubitemid 30151221)
34. Van de Kerkhof PCM, De Hoop D, De Korte J, et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000;200:292-298 •• One of the few papers assessing compliance behavior in psoriatic patients. (Pubitemid 30451575)
35. Naldi L, Rzany B. Chronic plaque psoriasis. Clin Evid 2006;15:2249-2283 • The chapter on psoriasis in BMJ Clinical Evidence, which has been defined as one of the world's most authoritative medical resources for informing treatment decisions and improving patient care.
36. Katz KA. 'Biologics': a clinically meaningless term. Br J Dermatol 2006;154:809-812 •• A nice provocative paper on the meaningless use of the term 'biologics'.
37. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systemic review. Br J Dermatol 2002;146:351-364 • All major medical databases of published literature were searched electronically for randomized clinical trials in this systematic review. (Pubitemid 34603806)
38. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr. A systematic review of adverse effects associated with topical treatments for psossriasis. Dermatol Online J 2003;9:2 • A review of medical literature from 1996 to March, 2002 conducted using guidelines set by QUORUM (Quality of Reporting of Meta-analyses) statement criteria. (Pubitemid 38888668)
39. Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007;299:111-138 • The guidelines of the main German Dermatological Societies, updated and evidence-based. (Pubitemid 46835379)
40. Ashcroft DM, Po AL, Williams HC, Griffiths CEM. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320:963-967 (Pubitemid 30192863)
41. Stern RS. Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med 2007;357:682-690 • A practical review starting with a clinical vignette. (Pubitemid 47267238)
42. Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004;151:283-297 (Pubitemid 39215142)
43. Taibjee SM, Cheung ST, Laube S, Lanigan SW. Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis. Br J Dermatol 2005;153:960-966 (Pubitemid 41540761)
44. Viola G, Fortunato E, Cecconet L, et al. Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544. Toxicol Appl Pharmacol 2008;227:84-96 (Pubitemid 351179847)
45. Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E, et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999;141:497-501 (Pubitemid 29448411)
46. Griffiths CEM, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4:1-125 (Pubitemid 32236838)
47. Naldi L, Griffiths CME. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005;152:597-615 (Pubitemid 40571289)
48. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus ciclosporin in moderate-to severe chronic plaque psoriasis. N Engl J Med 2003;349:658-665 (Pubitemid 36975998)
49. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-566 (Pubitemid 351239154)
50. Griffiths CEM, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004;150:11-23 • The main recommendation is to use ciclosporin in intermittent short courses (average of 12 weeks' duration). (Pubitemid 38903574)
51. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with ciclosporin: a 5 y cohort study. J Invest Dermatol 2003;120:211-216 (Pubitemid 36513069)
52. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003;121:1383-1388 (Pubitemid 38005490)
53. Gerdes S, Shakery K, Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein b in activated human T cells. Br J Dermatol 2007;156:838-842 (Pubitemid 46642827)
54. Tang H, Lu JY, Zheng X, et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun 2008;375:562-565
55. Mrowietz U, Altmeyer P, Bieber T, et al. Treatment of psoriasis with fumaric acid esters (Fumaderm). J Dtsch Dermatol Ges 2007;5:716-717 (Pubitemid 47099800)
56. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003;149:363-369 (Pubitemid 37100263)
57. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-497 • Clinical practice guidelines for using biological agents in the UK. (Pubitemid 41540798)
58. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10(46):1-233, i-iv
59. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285 •• A systematic review of randomized clinical trials of TNF-α antagonists, pointing to increased risk of severe infections and cancer. (Pubitemid 43736578)
60. Flendrie M, Vissers WHPM, Creemers MCW, et al. Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76 (DOI 10.1186/ar1724)
61. Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006;54:s171-81 • The National Psoriasis Foundation standardized definitions of relapse and rebound. (Pubitemid 43238300)
62. Gisondi P, Del Giglio M, Cotena C, Girolomoni GP. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008;158:1345-1349 (Pubitemid 351692891)
63. Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 2004;22:407-426 (Pubitemid 39140772)
64. Ellis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-255
65. Leonardi CL. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin 2004;22:427-435 (Pubitemid 39140773)
66. Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin 2004;22:449-459 (Pubitemid 39140774)
67. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-2022 (Pubitemid 37448924)
68. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35 (Pubitemid 43038667)
69. Winterfield L, Menter A. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade. Dermatol Clin 2004;22:437-447 (Pubitemid 39144390)
70. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-1847 (Pubitemid 32539117)
71. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-1374 (Pubitemid 41443403)
72. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56 31 :e1-15 (Pubitemid 44969297)
73. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind randomized controlled trial and open label extension study. J Am Acad Dermatol 2006;55:598-606 (Pubitemid 44436647)
74. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-115 (Pubitemid 350298146)
75. Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003;120:738-741 • A review of published clinical trials for psoriasis in terms of quality of reporting and relevance to clinical practice.
76. Kalorama Information. The Worldwide Market for prescription dermatological drugs, Fourth edition, February 2004, Kalorama Infornation, New York.
77. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-75 •• An excellent presentation of the immunopathogenesis of psoriasis, mainly represented as a T lymphocyte-mediated disorder, with the introducton of the unifying model of the 'cytokine network'.
78. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;455:866-873 •• The ultimate reference on the pathogenesis of psoriasis. (Pubitemid 46315823)
79. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006;54:S67-80 (Pubitemid 43243477)
80. Griffiths CE, Barker JN. Pathogenesis and clinical features sof psoriasis. Lancet 2007;370:263-271 (Pubitemid 47069537)
81. Li A, Simmons PJ, Kaur P. Identification and isolation of candidate human keratinocyte stem cells based on cell surface phenotype. Proc Natl Acad Sci USA 1998;95:3902-3907 (Pubitemid 28173226)
82. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-143 • This study presents experiments in a xenograft model demonstrating that plasmacytoid predendritic cells producing IFN-α are essential to drive the development of psoriasis in vivo, suggesting a novel innate immune pathway for triggering psoriasis. (Pubitemid 41002916)
83. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73 •• These authors introduced the concept of TH1 and TH2 cytokine network in immunopathology. (Pubitemid 19138011)
84. Tschachler E. Psoriasis: the epidermal component. Clin Dermatol 2007;25:589-595 (Pubitemid 350087609)
85. Nickoloff BJ. Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 2006;12:102-6 •• 'In complex diseases such as psoriasis, in which both barrier function and cutaneous inflammation are dysregulated, it is unclear whether the primary pathogenic disturbance resides in keratinocytes or in immunocytes'.
86. Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437(7057):369-375 •• A paper suggesting that the abrogation of JunB/activator protein 1(AP-1) in keratinocytes triggers chemokine/cytokine expression, which recruits neutrophils and macrophages to the epidermis, thereby contributing to the phenotypic changes observed in psoriasis. JunB is a gene localized in the psoriasis susceptibility region PSORS6. (Pubitemid 41613493)
87. Boniface K, Guignouard E, Pedretti N, et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007;150:407-415 (Pubitemid 350098734)
88. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-651 (Pubitemid 46232884)
89. Available from: http://www.clinicaltrials.gov/
90. Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther 2008;10:393-406
91. Melmed GY, Targan SR, Yasothan U, et al. Certolizumab pegol. Nat Rev Drug Discov 2008;7:641-642
92. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin 12/23 antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-592 (Pubitemid 46220818)
93. Papp KA, Langley RG, Lebwohl M, et al. PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-1684
94. Leonardi CL, Kimball AB, Papp KA, et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-1674
95. Kimball AB, Gordon KB, Langley RG, et al. ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-207
96. Wakkee M, Thio HB. Drug evaluation: BG-12, an immunomodulatory dimethylfumarate. Curr Opin Investig Drugs 2007;8:955-962
97. Papp K, Bissonette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008;371:1337-1342
98. Verfaille CJ, Thissen CA, Bovenschen HJ, et al. Oral R115866 in the treatment of moderate to severe plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007;21:1038-1046 (Pubitemid 47304603)
99. Bar-Yehuda S, Silverman MH, Kerns WD, et al. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs 2007;16:1601-1613 (Pubitemid 350028410)
100. Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008;155:288-290
101. Schieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005;5:921-928 (Pubitemid 41582124)
102. Tickenbrock L, Müller-Tidow C, Berdel WE, Serve H. Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opin Emerg Drugs 2006;11:153-165
103. Deuse T, Velotta JB, Hoyt G, et al. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation 2008;85:885-892
104. Skvara H, Dawid M, Kleyn E, et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008;118:3151-3159
105. Kurd SK, Smith N, VanVoorhees A, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol 2008;58:625-631
106. Williams B, Vanags D, Hall S, et al. Efficacy and safety of chaperonin 10 in patients with moderate to severe plaque psoriasis: evidence of utility beyond a single indication. Arch Dermatol 2008;144:683-685 (Pubitemid 351724437)
107. Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate, pyrimidine and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 2007;127:1860-1867 (Pubitemid 47075365)
108. De Vlam K, Gottlieb AB, Fitzgerald O. Biological biomarkers in psoriatic disease. A review. J Rheumatol 2008;35:1443-1448 •• The development of biomarkers lags behind that of drug development. There is an urgent need for development and validation of biomarkers in psoriasis. (Pubitemid 352000801)
109. Lecluse LL, Naldi L, Stern RS, Spuls PI. National registries of systemic treatment for Psoriasis and the European 'Psonet' initiative. Dermatology 2008 [Epub ahead of print] • Several European countries have established registries to collect data on systemic psoriasis treatment. Combining the results from these registries would increase their power and impact.